<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39346898</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Mechanism of emodin in treating hepatitis B virus-associated hepatocellular carcinoma: network pharmacology and cell experiments.</ArticleTitle><Pagination><StartPage>1458913</StartPage><MedlinePgn>1458913</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1458913</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2024.1458913</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Hepatocellular carcinoma (HCC) is a pressing global issue, with Hepatitis B virus (HBV) infection remaining the primary. Emodin, an anthraquinone compound extracted from the natural plant's. This study investigates the molecular targets and possible mechanisms of emodin in treating HBV-related HCC based on network pharmacology and molecular docking and validates the screened molecular targets through <i>in vitro</i> experiments.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Potential targets related to emodin were obtained through PubChem, CTD, PharmMapper, SuperPred, and TargetNet databases. Potential disease targets for HBV and HCC were identified using the DisGeNET, GeneCards, OMIM, and TTD databases. A Venn diagram was used to determine overlapping genes between the drug and the diseases. Enrichment analysis of these genes was performed using GO and KEGG via bioinformatics websites. The overlapping genes were imported into STRING to construct a protein-protein interaction network. Cytoscape 3.9.1 software was used for visualizing and analyzing the core targets. Molecular docking analysis of the drug and core targets was performed using Schrodinger. The regulatory effects of emodin on these core targets were validate through <i>in vitro</i> experiments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 43 overlapping genes were identified. GO analysis recognized 926 entries, and KEGG analysis identified 135 entries. The main pathways involved in the KEGG analysis included cancer, human cytomegalovirus infection and prostate cancer. The binding energies of emodin with HSP90AA1, PTGS2, GSTP1, SOD2, MAPK3, and PCNA were all less than -5 kcal/mol. Compared to normal liver tissue, the mRNA levels of XRCC1, MAPK3, and PCNA were significantly elevated in liver cancer tissue. The expression levels of XRCC1, HIF1A, MAPK3, and PCNA genes were closely related to HCC progression. High expressions of HSP90AA1, TGFB1, HIF1A, MAPK3, and PCNA were all closely associated with poor prognosis in HCC. <i>In vitro</i> experiments demonstrated that emodin significantly downregulated the expression of HSP90AA1, MAPK3, XRCC1, PCNA, and SOD2, while significantly upregulating the expression of PTGS2 and GSTP1.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study, based on network pharmacology and molecular docking validation, suggests that emodin may exert therapeutic effects on HBV-related HCC by downregulating the expression of XRCC1, MAPK3, PCNA, HSP90AA1, and SOD2, and upregulating the expression of PTGS2 and GSTP1.</AbstractText><CopyrightInformation>Copyright © 2024 Wang, Li, Ren, Zhang, Li and Geng.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Yupeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Shuangxing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Tianqi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yikun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Geng</LastName><ForeName>Xingchao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>KA46RNI6HN</RegistryNumber><NameOfSubstance UI="D004642">Emodin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018809">Proliferating Cell Nuclear Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000629262">PCNA protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004642" MajorTopicYN="Y">Emodin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="Y">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006515" MajorTopicYN="Y">Hepatitis B virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="Y">Protein Interaction Maps</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091484" MajorTopicYN="Y">Network Pharmacology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018809" MajorTopicYN="N">Proliferating Cell Nuclear Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">a systematic study</Keyword><Keyword MajorTopicYN="N">emodin</Keyword><Keyword MajorTopicYN="N">hepatitis B virus-related hepatocellular carcinoma</Keyword><Keyword MajorTopicYN="N">molecular docking validation</Keyword><Keyword MajorTopicYN="N">network pharmacology</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>17</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39346898</ArticleId><ArticleId IdType="pmc">PMC11427391</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2024.1458913</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amberger J. S., Bocchini C. A., Schiettecatte F., Scott A. F., Hamosh A. (2015). OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 43, D789–D798. doi: 10.1093/nar/gku1205</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1205</ArticleId><ArticleId IdType="pmc">PMC4383985</ArticleId><ArticleId IdType="pubmed">25428349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardou P., Mariette J., Escudié F., Djemiel C., Klopp C. (2014). jvenn: an interactive Venn diagram viewer. BMC Bioinf. 15, 293. doi: 10.1186/1471-2105-15-293</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-15-293</ArticleId><ArticleId IdType="pmc">PMC4261873</ArticleId><ArticleId IdType="pubmed">25176396</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan T. M., Leung J. K., Tsang R. C., Liu Z. H., Li L. S., Yung S. (2003). Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int. 64, 519–533. doi: 10.1046/j.1523-1755.2003.00113.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2003.00113.x</ArticleId><ArticleId IdType="pubmed">12846747</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Chen H., Wang K., Zhang L., Huang Z., Liu J. (2019). Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma. J. Hepatol. 70, 66–77. doi: 10.1016/j.jhep.2018.09.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2018.09.022</ArticleId><ArticleId IdType="pubmed">30287340</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis A. P., Wiegers T. C., Johnson R. J., Sciaky D., Wiegers J., Mattingly C. J. (2023). Comparative toxicogenomics database (CTD): update 2023. Nucleic Acids Res. 51, D1257–D1262. doi: 10.1093/nar/gkac833</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac833</ArticleId><ArticleId IdType="pmc">PMC9825590</ArticleId><ArticleId IdType="pubmed">36169237</ArticleId></ArticleIdList></Reference><Reference><Citation>de Martel C., Maucort-Boulch D., Plummer M., Franceschi S. (2015). World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatol. (Baltimore. Md.) 62, 1190–1200. doi: 10.1002/hep.27969</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.27969</ArticleId><ArticleId IdType="pmc">PMC5019261</ArticleId><ArticleId IdType="pubmed">26146815</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Dato F., Iorio R. (2024). Expanding indications for chronic hepatitis B treatment: Is it really desirable to treat everyone? World J. GASTROENTERO. 30, 2294–2297. doi: 10.3748/wjg.v30.i17.2294</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v30.i17.2294</ArticleId><ArticleId IdType="pmc">PMC11130575</ArticleId><ArticleId IdType="pubmed">38813053</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Z., Kihara D. (2019). Computational identification of protein-protein interactions in model plant proteomes. Sci. REP-UK. 9, 8740. doi: 10.1038/s41598-019-45072-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-45072-8</ArticleId><ArticleId IdType="pmc">PMC6584649</ArticleId><ArticleId IdType="pubmed">31217453</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X., Fu J., Yin X., Cao S., Li X., Lin L. (2016). Emodin: A review of its pharmacology, toxicity and pharmacokinetics. Phytother. Res.: PTR. 30, 1207–1218. doi: 10.1002/ptr.5631</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.5631</ArticleId><ArticleId IdType="pmc">PMC7168079</ArticleId><ArticleId IdType="pubmed">27188216</ArticleId></ArticleIdList></Reference><Reference><Citation>Duvoix A., Delhalle S., Blasius R., Schnekenburger M., Morceau F., Fougere M. (2004). Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappaB inhibition. Biochem. Pharmacol. 68, 1101–1111. doi: 10.1016/j.bcp.2004.05.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2004.05.032</ArticleId><ArticleId IdType="pubmed">15313406</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Z., Chen J., Yang Q., He J. (2022). Network pharmacology and experimental validation to reveal the pharmacological mechanisms of chongcaoyishen decoction against chronic kidney disease. Front. Mol. Biosci. 9, 847812. doi: 10.3389/fmolb.2022.847812</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.847812</ArticleId><ArticleId IdType="pmc">PMC9008695</ArticleId><ArticleId IdType="pubmed">35433831</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsythe J. A., Jiang B. H., Lyer N., Agani F., Leung S., Koos R., et al. . (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16, 4604–4613. doi: 10.1128/MCB.16.9.4604</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.16.9.4604</ArticleId><ArticleId IdType="pmc">PMC231459</ArticleId><ArticleId IdType="pubmed">8756616</ArticleId></ArticleIdList></Reference><Reference><Citation>Győrffy B. (2023). Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. GEROSCIENCE 45, 1889–1898. doi: 10.1007/s11357-023-00742-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-023-00742-4</ArticleId><ArticleId IdType="pmc">PMC10400493</ArticleId><ArticleId IdType="pubmed">36856946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi Goradel N., Najafi M., Salehi E., Farhood B., Mortezaee K. (2019). Cyclooxygenase-2 in cancer: A review. J. Cell Physiol. 234, 5683–5699. doi: 10.1002/jcp.27411</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27411</ArticleId><ArticleId IdType="pubmed">30341914</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu N., Liu J., Xue X., Li Y. (2020). The effect of emodin on liver disease – comprehensive advances in molecular mechanisms. Eur. J. Pharmacol. 882, 173269. doi: 10.1016/j.ejphar.2020.173269</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173269</ArticleId><ArticleId IdType="pubmed">32553811</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu H., Song X., Li Y., Ma T., Bai H., Zhao M. (2021). Emodin protects knee joint cartilage in rats through anti-matrix degradation pathway: An in vitro and in vivo study. Life Sci. 269, 119001. doi: 10.1016/j.lfs.2020.119001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.119001</ArticleId><ArticleId IdType="pubmed">33421527</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo C., Annunziata M., Melara G., Sciorio R., Dallio M., Masarone M. (2021). The role of resveratrol in liver disease: A comprehensive review from in vitro to clinical trials. NUTRIENTS 13. doi: 10.3390/nu13030933</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13030933</ArticleId><ArticleId IdType="pmc">PMC7999728</ArticleId><ArticleId IdType="pubmed">33805795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M., Sato Y., Kawashima M. (2022). KEGG mapping tools for uncovering hidden features in biological data. Protein Sci. 31, 47–53. doi: 10.1002/pro.4172</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.4172</ArticleId><ArticleId IdType="pmc">PMC8740838</ArticleId><ArticleId IdType="pubmed">34423492</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan H., Ullah H., Nabavi S. M. (2019). Mechanistic insights of hepatoprotective effects of curcumin: Therapeutic updates and future prospects. Food Chem. Toxicol. 124, 182–191. doi: 10.1016/j.fct.2018.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2018.12.002</ArticleId><ArticleId IdType="pubmed">30529260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo T., Yang J., Lin M., Hsu S., Lin J., Lin H. (2009). Emodin has cytotoxic and protective effects in rat C6 glioma cells: roles of Mdr1a and nuclear factor kappaB in cell survival. J. Pharmacol. Exp. Ther. 330, 736–744. doi: 10.1124/jpet.109.153007</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.109.153007</ArticleId><ArticleId IdType="pubmed">19549930</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Song Q., Ji X., Lyu Y., Lai Y. S., Zuo Z. (2022). 2,3,5,4’-tetrahydroxystilbene-2-O-β-D-glucopyranoside enhances the hepatotoxicity of emodin in vitro and in vivo . Toxicol. Lett. 365, 74–85. doi: 10.1016/j.toxlet.2022.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxlet.2022.06.008</ArticleId><ArticleId IdType="pubmed">35753641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L., Li H., Lin H., Zhang M., Qu C., Yan L. (2017). A new perspective on liver injury by traditional chinese herbs such as polygonum multiflorum: the geographical area of harvest as an important contributory factor. Front. Pharmacol. 8. doi: 10.3389/fphar.2017.00349</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00349</ArticleId><ArticleId IdType="pmc">PMC5476691</ArticleId><ArticleId IdType="pubmed">28676759</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Tan N., Liao H., Pan G., Xu Q., Zhu R. (2018). High GSTP1 inhibits cell proliferation by reducing Akt phosphorylation and is associated with a better prognosis in hepatocellular carcinoma. Oncotarget 9, 8957–8971. doi: 10.18632/oncotarget.v9i10</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.v9i10</ArticleId><ArticleId IdType="pmc">PMC5823662</ArticleId><ArticleId IdType="pubmed">29507666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Z., Xiang X., Li S., Xie P., Gong Q., Goh B. (2022). Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds. Semin. Cancer Biol. 80, 379–390. doi: 10.1016/j.semcancer.2020.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2020.09.011</ArticleId><ArticleId IdType="pubmed">33002608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S., Yang J., Li J., Song J. (2016). The clinical utility of the proliferating cell nuclear antigen expression in patients with hepatocellular carcinoma. Tumour. Biol. 37, 7405–7412. doi: 10.1007/s13277-015-4582-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-015-4582-9</ArticleId><ArticleId IdType="pubmed">26676639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei J., Wang H., Wang R., Pan J., Liu C., Xu J. (2020). Evaluation of X-ray repair cross-complementing family members as potential biomarkers for predicting progression and prognosis in hepatocellular carcinoma. BioMed. Res. Int. 5751939, 2020. doi: 10.1155/2020/5751939</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5751939</ArticleId><ArticleId IdType="pmc">PMC7103035</ArticleId><ArticleId IdType="pubmed">32258128</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng K., Lv Y., Yu L., Wu S., Pan C. (2005). Effects of emodin and double blood supplies on liver regeneration of reduced size graft liver in rat model. World J. GASTROENTERO. 11, 2941–2944. doi: 10.3748/wjg.v11.i19.2941</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v11.i19.2941</ArticleId><ArticleId IdType="pmc">PMC4305663</ArticleId><ArticleId IdType="pubmed">15902732</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickel J., Gohlke B., Erehman J., Banerjee P., Rong W., Goede A. (2014). SuperPred: update on drug classification and target prediction. Nucleic Acids Res. 42, W26–W31. doi: 10.1093/nar/gku477</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku477</ArticleId><ArticleId IdType="pmc">PMC4086135</ArticleId><ArticleId IdType="pubmed">24878925</ArticleId></ArticleIdList></Reference><Reference><Citation>Paggi J. M., Pandit A., Dror R. O. (2024). The art and science of molecular docking. Annu. Rev. Biochem. 93 (1), 389–410. doi: 10.1146/annurev-biochem-030222-120000</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-030222-120000</ArticleId><ArticleId IdType="pubmed">38594926</ArticleId></ArticleIdList></Reference><Reference><Citation>Piñero J., Saüch J., Sanz F., Furlong L. I. (2021). The DisGeNET cytoscape app: Exploring and visualizing disease genomics data. Comput. Struct. BIOTEC. 19, 2960–2967. doi: 10.1016/j.csbj.2021.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2021.05.015</ArticleId><ArticleId IdType="pmc">PMC8163863</ArticleId><ArticleId IdType="pubmed">34136095</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo G. E. M., Cabibbo G., Craxì A. (2022). Hepatitis B virus-associated hepatocellular carcinoma. VIRUSES-BASEL 14. doi: 10.3390/v14050986</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14050986</ArticleId><ArticleId IdType="pmc">PMC9146458</ArticleId><ArticleId IdType="pubmed">35632728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarin S. K., Kumar M., Lau G. K., Abbas Z., Chan H., Chen C. (2016). Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 10, 1–98. doi: 10.1007/s12072-015-9675-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-015-9675-4</ArticleId><ArticleId IdType="pmc">PMC4722087</ArticleId><ArticleId IdType="pubmed">26563120</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmierer B., Hill C. S. (2007). TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nature reviews. Mol. Cell Biol. 8, 970–982. doi: 10.1038/nrm2297</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2297</ArticleId><ArticleId IdType="pubmed">18000526</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L., Wang Y., Li J., Zhou F., Xiao K., Liu Y. (2023). Mechanism of Sijunzi Decoction in the treatment of colorectal cancer based on network pharmacology and experimental validation. J. ETHNOPHARMACOL. 302, 115876. doi: 10.1016/j.jep.2022.115876</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2022.115876</ArticleId><ArticleId IdType="pubmed">36343798</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P., Markiel A., Ozier O., Baliga N., Wang J., Ramage D. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504. doi: 10.1101/gr.1239303</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Q., Liu T., Wang W., Liu T., Jin X., Chen Z. (2022). Promising role of emodin as therapeutics to against viral infections. Front. Pharmacol. 13, 902626. doi: 10.3389/fphar.2022.902626</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.902626</ArticleId><ArticleId IdType="pmc">PMC9115582</ArticleId><ArticleId IdType="pubmed">35600857</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuangsuo D., Zhengguo Z., Yunru C., Xin Z., Baofeng W., Lichao Y. (2006). Inhibition of the replication of hepatitis B virus in vitro by emodin. Med. Sci. Monitor. 12, BR302–BR306.</Citation><ArticleIdList><ArticleId IdType="pubmed">16940925</ArticleId></ArticleIdList></Reference><Reference><Citation>Stelzer G., Rosen N., Plaschkes I., Zimmerman S., Twik M., Fishilevich S. (2016). The geneCards suite: from gene data mining to disease genome sequence analyses. Curr. Protoc. Bioinf. 54, 1–30. doi: 10.1002/cpbi.5</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpbi.5</ArticleId><ArticleId IdType="pubmed">27322403</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z., Li C., Kang B., Gao G., Li C., Zhang Z. (2017). GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98–102. doi: 10.1093/nar/gkx247</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx247</ArticleId><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao N., Zhou H., Tang H., Cai X., Zhang W., Ren J. (2016). Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway. Oncotarget 7, 50117–50130. doi: 10.18632/oncotarget.v7i31</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.v7i31</ArticleId><ArticleId IdType="pmc">PMC5226572</ArticleId><ArticleId IdType="pubmed">27367026</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrault N. A., Lok A. S. F., McMahon B. J., Chang K. M., Hwang J. P., Maureen M. J. (2018). Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatol. (Baltimore. Md.) 67, 1560–1599. doi: 10.1002/hep.29800</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.29800</ArticleId><ArticleId IdType="pmc">PMC5975958</ArticleId><ArticleId IdType="pubmed">29405329</ArticleId></ArticleIdList></Reference><Reference><Citation>Tufegdzic Vidakovic A., Rueda O. M., Vervoort S. J., Batra A. S., Goldgraben M. A., Lewis S. U., et al. . (2015). Context-specific effects of TGF-β/SMAD3 in cancer are modulated by the epigenome. Cell Rep. 13, 2480–2490. doi: 10.1016/j.celrep.2015.11.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.11.040</ArticleId><ArticleId IdType="pmc">PMC4695334</ArticleId><ArticleId IdType="pubmed">26686634</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuli H. S., Aggarwal V., Tuorkey M., Aggarwal D., Parashar N. C., Varol M., et al. . (2021). Emodin: A metabolite that exhibits anti-neoplastic activities by modulating multiple oncogenic targets. Toxicol. Vitro 73, 105142. doi: 10.1016/j.tiv.2021.105142</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tiv.2021.105142</ArticleId><ArticleId IdType="pubmed">33722736</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlén M., Fagerberg L., Hallström B. M., Lindskog C., Oksvold P., Mardinoglu A., et al. . (2015). Proteomics. Tissue-based map of the human proteome. Sci. (New. York. N.Y.). 347, 1260419. doi: 10.1126/science.1260419</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1260419</ArticleId><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Deng B. (2023). Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis. Rev. 42, 629–652. doi: 10.1007/s10555-023-10084-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10555-023-10084-4</ArticleId><ArticleId IdType="pubmed">36729264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Shen Y., Wang S., Li S., Zhang W., Liu X., et al. . (2017). PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 45, W356–W360. doi: 10.1093/nar/gkx374</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx374</ArticleId><ArticleId IdType="pmc">PMC5793840</ArticleId><ArticleId IdType="pubmed">28472422</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Yin C., Li X., Yang X. Z., Yang Y., Zhang M. Y., et al. . (2016). Reduced SOD2 expression is associated with mortality of hepatocellular carcinoma patients in a mutant p53-dependent manner. Aging 8, 1184–1200. doi: 10.18632/aging.v8i6</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.v8i6</ArticleId><ArticleId IdType="pmc">PMC4931826</ArticleId><ArticleId IdType="pubmed">27221200</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse C. J., Taylor R. M., Thistlethwaite A., Zhang H., Busheri F. K., Lasko D. D., et al. . (2001). XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. CELL 104, 107–117. doi: 10.1016/S0092-8674(01)00195-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(01)00195-7</ArticleId><ArticleId IdType="pubmed">11163244</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X., Zhang N., Li X., Huang H., Peng C., Huang W., et al. . (2023). Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy. BIOORG. Chem. 139, 106721. doi: 10.1016/j.bioorg.2023.106721</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioorg.2023.106721</ArticleId><ArticleId IdType="pubmed">37467620</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Sun Q., Qiu M., Wu Y., Cheng L., Jiang N., et al. . (2024). Exploring the pharmacological mechanism of Glycyrrhiza uralensis against KOA through integrating network pharmacology and experimental assessment. J. Cell Mol. Med. 28, e18319. doi: 10.1111/jcmm.18319</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.18319</ArticleId><ArticleId IdType="pmc">PMC11092526</ArticleId><ArticleId IdType="pubmed">38742846</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Zheng L., Chng W. J., Ding J. L. (2019). Comprehensive analysis of ERK1/2 substrates for potential combination immunotherapies. Trends Pharmacol. Sci. 40, 897–910. doi: 10.1016/j.tips.2019.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2019.09.005</ArticleId><ArticleId IdType="pubmed">31662208</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Z., Dong J., Che Y., Zhu M. F., Wen M., Wang N. N., et al. . (2016). TargetNet: a web service for predicting potential drug-target interaction profiling via multi-target SAR models. J. Comput. AID. Mol. Des. 30, 413–424. doi: 10.1007/s10822-016-9915-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10822-016-9915-2</ArticleId><ArticleId IdType="pubmed">27167132</ArticleId></ArticleIdList></Reference><Reference><Citation>Yon J., Baek I., Lee B. J., Yun Y. W., Nam S. (2011). Emodin and [6]-gingerol lessen hypoxia-induced embryotoxicities in cultured mouse whole embryos via upregulation of hypoxia-inducible factor 1α and intracellular superoxide dismutases. Reprod. Toxicol. (Elmsford. N.Y.). 31, 513–518. doi: 10.1016/j.reprotox.2011.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reprotox.2011.02.011</ArticleId><ArticleId IdType="pubmed">21382473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Yang X., Dai Y., Xiao H. (2019). Effects of emodin on lipid accumulation and inflammation in hepatocytes. Zhongguo. Zhong. Yao. Za. Zhi. = Zhongguo. Zhongyao. Zazhi. = China J. Chin. Materia. Med. 44, 2820–2826. doi: 10.19540/j.cnki.cjcmm.20190321.401</Citation><ArticleIdList><ArticleId IdType="doi">10.19540/j.cnki.cjcmm.20190321.401</ArticleId><ArticleId IdType="pubmed">31359696</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Zhao E., Zhang J., Chen Y., Ma J., Li H. (2019). A comprehensive evaluation of the association between polymorphisms in XRCC1, ERCC2, and XRCC3 and prognosis in hepatocellular carcinoma: A meta-analysis. J. Oncol. 2408946, 2019. doi: 10.1155/2019/2408946</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/2408946</ArticleId><ArticleId IdType="pmc">PMC6594280</ArticleId><ArticleId IdType="pubmed">31281357</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S., Ai Z., Li W., You P., Wu C., Li L., et al. . (2020). Deciphering the pharmacological mechanisms of taohe-chengqi decoction extract against renal fibrosis through integrating network pharmacology and experimental validation in vitro and in vivo . Front. Pharmacol. 11, 425. doi: 10.3389/fphar.2020.00425</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00425</ArticleId><ArticleId IdType="pmc">PMC7176980</ArticleId><ArticleId IdType="pubmed">32372953</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Yeasmin Khusbu F., Xie Y., Yang P. (2023). Emodin-induced necroptosis in prostate cancer cells via the mitochondrial fission HSP90/MLKL/PGAM pathway. Chem. BIODIVERS. 20, e202201130. doi: 10.1002/cbdv.202201130</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbdv.202201130</ArticleId><ArticleId IdType="pubmed">37062702</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Zhang Y., Lian X., Li F., Wang C., Zhu F., et al. . (2022). Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res. 50, D1398–D1407. doi: 10.1093/nar/gkab953</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab953</ArticleId><ArticleId IdType="pmc">PMC8728281</ArticleId><ArticleId IdType="pubmed">34718717</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuehlke A. D., Beebe K., Neckers L., Prince T. (2015). Regulation and function of the human HSP90AA1 gene. GENE 570, 8–16. doi: 10.1016/j.gene.2015.06.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.06.018</ArticleId><ArticleId IdType="pmc">PMC4519370</ArticleId><ArticleId IdType="pubmed">26071189</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>